New service: competitor analysis of targeted immunotherapies with targets selected by clients STUTTGART, Germany I September 01, 2025 I La Merie Publishing announced the launch of its newest service offering of reviewing the pipeline of immunotherapeutics for targets selected by clients: Pipeline Review of Customer-Selected Targeted Immunotherapies: Pre-Scoped Competitor Analysis....

KLK2: promising drug target in prostate cancer – a pipeline review STUTTGART, Germany I August 31, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-KLK2 immunotherapeutics in R&D: Pipeline of KLK2-Targeted Immunotherapies. This competitive intelligence report about Pipeline of KLK2-Targeted...

Vectorized antibodies by in vivo expression of DNA or RNA overcome limitations of systemically administered antibodies STUTTGART, Germany I August 30, 2025 I Antibodies as a drug modality in general have become extremely successful in terms of clinically effective therapies and of market size. The global market size of all...

STEAP1 and STEAP2: emerging prostate cancer targets – a pipeline review STUTTGART, Germany I August 30, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-STEAP1- and/or STEAP2 immunotherapeutics in R&D: Pipeline of STEAP1- and STEAP2-Targeted Immunotherapies. This competitive intelligence report...

Tissue Factor: a validated target for improved solid tumor antibody-drug conjugates – a pipeline review STUTTGART, Germany I August 27, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-Tissue Factor immunotherapeutics in R&D: Pipeline of Tissue Factor-Targeted Immunotherapies. This competitive...

CD38: a Blockbuster sales target under fire by biosuperior and biosmilar antibody competitors – a pipeline review STUTTGART, Germany I August 26, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-CD38 immunotherapeutics in R&D: Pipeline of CD38-Targeted Immunotherapies. This competitive...

TROP-2: a Blockbuster target with opportunities for new drug modalities – a pipeline review STUTTGART, Germany I August 26, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-TROP-2 immunotherapeutics in R&D: Pipeline of TROP-2-Targeted Immunotherapies. This competitive intelligence report about...

Nectin-4: a clinically and commercially validated target with limited competition – a pipeline review STUTTGART, Germany I August 26, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-nectin-4 immunotherapeutics in R&D: Pipeline of Nectin-4-Targeted Immunotherapies. This competitive intelligence report about...

CCR8: an attractive immuno-oncology target for antibody therapy – a pipeline review STUTTGART, Germany I August 20, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-CCR8 immunotherapeutics in R&D: Pipeline of CCR8-Targeted Immunotherapies. This competitive intelligence report about CCR8-Targeted Immunotherapies...

EpCAM: conditional activation technologies can make EpCAM a viable target – a pipeline review STUTTGART, Germany I August 19, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-EpCAM immunotherapeutics in R&D: Pipeline of EpCAM-Targeted Immunotherapies. This competitive intelligence report about...